Publikationer

1970-talet

Jansen H, Berseus O, Johansson JE. A simple photometric method for determination of blood loss during transurethral surgery. Scand J Urol Nephrol 1978;12(1):1-5.

1980-talet

Johansson JE, Beckman KW, Lindell D, Lingårdh, Rydman H, Vikterlöf KJ. Serial bone scanning in the evaluation of stage and clinical course in carcinoma of the prostate. Scand J Urol Nephrol Suppl 1980;55:31-6.

Johansson JE, Lannes P. Metastases to the spermatic cord, epididymis and testicles from carcinoma of the prostate--five cases. Scand J Urol Nephrol 1983;17(2):249-51.

Brehmer-Andersson E, Andersson L, Johansson JE. Hemorrhagic infarctions of testis due to intimal fibroplasia of spermatic artery. Urology 1985;25(4):379-82.

Johansson JE, Lingårdh G. High-dose medroxyprogesterone in the treatment of advanced therapy-resistant prostatic carcinoma. Eur Urol 1985;11(1):9-10.

Johansson JE, Andersson SO, Beckman KW, Lingårdh G, Zador G. Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. Urology 1987;29(1):55-9.

Johansson JE, Andersson SO, Beckman KW, Zador G. Clinical evaluation with long-term follow-up of flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate. Am J Clin Oncol 1988;11 Suppl 2:S183-6.

Johansson JE, Andersson SO, Kraaz W, Schnürer LB. Wait and see in early prostatic cancer. Preliminary report of a 7-year material of 223 patients. Scand J Urol Nephrol Suppl 1988;110:77-81.

Stegmayr B, Johansson JE, Schnürer LB. Flutamide--an antiandrogen inhibiting prostatic cancer and prostatic secretion with retention of potency. Med Oncol Tumor Pharmacother 1988;5(1):61-5.

Johansson JE, Adami HO, Andersson SO, Bergström R, Krusemo UB, Kraaz W. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet 1989;1(8642):799-803.

1990-talet

Hedlund PO, Esposti P, Falkmer U, Jacobsson H, (Johansson JE), Scandinavian Prostate Cancer Group. DNA as a prognostic marker in advanced high-grade prostatic cancer. A preliminary report. SPCG-I study. Acta Oncol 1991;30(2):215-7.

Johansson JE. Natural history, palliative treatment and prognostic factors in prostatic cancer : a population-based study from Örebro, Sweden [dissertation]. Uppsala: Uppsala University; 1991.

Johansson JE, Andersson SO. Deferred treatment in localized prostatic cancer. Acta Oncol 1991;30(2):221-3.

Johansson JE, Andersson SO, Holmberg L. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. Br J Urol 1991;68(1):67-73.

Johansson JE, Andersson SO, Holmberg L, Bergström R. Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. J Urol 1991;146(5):1327-32; discussion 32-3.

Johansson JE, Andersson SO, Holmberg L, Bergström R. Primary orchiectomy versus estrogen therapy in advanced prostatic cancer--a randomized study: results after 7 to 10 years of followup. J Urol 1991;145(3):519-22; discussion 22-30.

Nydahl PA, Philipson L, Axelsson K, Johansson JE. Epidural anesthesia with 0.5% bupivacaine: influence of age on sensory and motor blockade. Anesth Analg 1991;73(6):780-6.

Odelberg-Johnson O, Underskog I, Johansson JE, Bernshaw D, Sorbe B, Persson JE. Intracavitary irradiation of prostatic carcinoma by a high dose-rate afterloading technique. Acta Oncol 1991;30(1):45-50.

Carringer M, Pedersen J, Schnurer L-B. Autotransposition of vas in a 2-stage procedure. Scand J Urol Nephrol 1992;26:227-230.

Holmberg L, Pahlman L, Johansson JE, Westman G. Efterkontroller vid behandling for cancer behöver kritiskt utvärderas. Lakartidningen 1992;89(16):1371-4.

Johansson JE. Observera eller operera vid tidig prostatacancer? Läkartidningen 1992;89(45):3805-6.

Johansson JE, Adami HO, Andersson SO, Bergström R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267(16):2191-6.

Johansson JE, Sigurdsson T, Holmberg L, Bergström R. Erythrocyte sedimentation rate as a tumor marker in human prostatic cancer. An analysis of prognostic factors in 300 population-based consecutive cases. Cancer 1992;70(6):1556-63.

S-O Andersson, R Bergström, L Wide and H-O Adami. Serum pituitary and sex steroid hormones in the etiology of prostate cancer - a population-based case-control study in Sweden. Br J Cancer 68;97-102,1993.

T.Windahl, L. Löfgren. Two years experience with photodynamic therapy of bladder carcinoma. Brit.J.Urol  71,187-191 (1993)

T. Windahl, Q.Peng, J.Moan, S.Hellsten, B.Axelsson,L.Löfgren. Uptake and distribution of intravenously  and intravesically administered photosensitizers in the rat. Cancer Letters 75, 65-70 (1993)

S-O Andersson, T.Windahl, J-E Johansson. Neodymium- YAG laser treatment in localized prostatic carcinoma. Scand.J.Urol.Nephrol 27:485-487, (1993)

Andersson SO, Johansson JE, Windahl T. Neodymium-YAG laser treatment in localized prostatic cancer. High rate of local failure. Scand J Urol Nephrol 1993;27(4):485-7.

T.Windahl, S.Hellsten. Carbone dioxide laser treatment of lichen sclerosus and atrophicus. J.Urol,vol 150, 868-870, (1993)

Jahnson S, Johansson JE. Results of window operation for primary hydrocele. Urology 1993;41(1):27-8.

Chisholm GD, Hedlund PO, Adolfsson J, Denis LJ, Friberg S, Johansson JE, et al. The TNM system of 1992. Comments from the TNM working group. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl 1994;162:107-14; discussion 15-27.

Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330(4):242-8.

Johansson JE. Expectant management of early stage prostatic cancer: Swedish experience. J Urol 1994;152(5 Pt 2):1753-6.

Johansson JE. Watchful waiting for early stage prostate cancer. Urology 1994;43(2):138-42.

Sigurdsson T, Johansson JE, Jahnson S, Helgesen F, Andersson SO. Polidocanol sclerotherapy for hydroceles and epididymal cysts. J Urol 1994;151(4):898-901.

Carringer M, Pedersen J, Schnurer L-B. Experimental vas replacement by either vas or a vascular graft. Scand J Urol Nephrol 1995; 29: 97-102.

S-O Andersson, J Baron, A Wolk, C Lindgren, R Bergström and H-O Adami Early life risk factors for prostate cancer: a population based case-control study in Sweden.  Cancer Epidemiol Biomarkers and Prevention 4;187-92.1995.

T.Windahl, S.Hellsten. Lasertreatment of localized squamous cell carcinoma of the penis. J.Urol, vol 154,1020-1023, (1995)

Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology 1995;46(5):631-7.

Johansson JE, Abrahamsson PA, Adami HO, Adolfsson J, Carlsson P, Damber JE, et al. Massundersökning för prostatacancer. Stockholm: Statens beredning för utvärdering av medicinsk metodik (SBU); 1995. (SBU-rapport ; 126).

Carringer M, Pedersen J, Schnürer L-B. Fertility after autotransposition of vas: a comparative studyof absorbable and nonabsorbable suture material in rats. Scand J Urol Nephrol. 1996;30:15-18.

Carringer M, Swartz R, Johansson J E. Management of ureteric calculi during pregnancy by ureteroscopy and laser lithotripsy.  Br J Urol (1996), 77, 17-20.

S-O Andersson, J Baron, R Bergström, C Lindgren, A Wolk and H-O Adami. Lifestyle factors and prostate cancer risk: a case-control study in Sweden. Cancer Epidemiol Biomarkers and Prevention5; 509-13.1996

E.Esbjörner, T.Andersson, A.Hussein, T.Windahl. Xanthogranulomatous pyelonephritis- an unusal renal disease in childhood. Acta Pediatrica 85: 258-260, (1996)

Andersen JT, Wolf H, Ekman P, Beisland HO, Johansson JE, Kontturi M, et al. Finasterid ved symptomgivende benign prostatahypertrofi. Et toårs placebokontrolleret studie. Skandinaviske BPH-Studiegruppe. Ugeskr Laeger 1996;158(36):5030-5.

Carringer M, Swartz R, Johansson JE. Management of ureteric calculi during pregnancy by ureteroscopy and laser lithotripsy. Br J Urol 1996;77(1):17-20.

Helgesen F, Holmberg L, Johansson JE, Bergström R, Adami HO. Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst 1996;88(17):1216-21.

Iversen P, Tveter K, Varenhorst E, Scandinavian Casodex Cooperative Group. Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scand J Urol Nephrol 1996;30(2):93-8.

Johansson JE. Natürlicher Verlauf des unbehandelten, lokal begrenzten primären Prostatakarzinoms. Urologe A 1996;35(6):446-8.

The Swedish Council on Technology Assessment in Health Care (Johansson JE chairman). Mass screening for prostate cancer. Int J Cancer Suppl 1996;9:1-72.

Tveter KJ, Beisland HO, Andersen JT, Wolf H, Ekman P, Johansson JE, et al. Behandling av benign prostatahyperplasi med Proscar (finasterid). Resultater av en toårig skandinavisk undersøkelse. Tidsskr Nor Laegeforen 1996;116(27):3226-30.

Carringer M, Hedlund P, Pedersen J. Autonomic innervation of vas deferens afterautotransposition: a functional study in the rat. Scand J Urol Nephrol 1997;31:523-528.

A Wolk, S-O Andersson, R Bergström Re: Prospective study of sex hormone levels and risk of prostate cancer. JNCI 89;820.1997

S-O Andersson, A Wolk, R Bergström, H-O Adami, G Engholm, A Englund, O Nyrén Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. JNCI 5;385-89.1997.

Hägglöf B, Andrén O, Bergström E, Marklund L, Wendelius M. Self-esteem before and after treatment in children with nocturnal enuresis and urinary incontinence. Scand J Urol Nephrol Suppl 1997;183:79-82.

Blomqvist P, Ekbom A, Carlsson P, Ahlstrand C, Johansson JE. Benign prostatic hyperplasia in Sweden 1987 to 1994: changing patterns of treatment, changing patterns of costs. Urology 1997;50(2):214-9; discussion 9-20.

Hedlund PO, Jacobsson H, Vaage S, Hahne B, Sandin T, (Johansson, JE) Scandinavian Prostate Cancer Group, et al. Treatment of high-grade, high-stage prostate cancer with estramustine phosphate or diethylstilbestrol. A double-blind study. The SPCG-1 Study Group. Scandinavian Prostate Cancer Group. Scand J Urol Nephrol 1997;31(2):167-72.

Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277(6):467-71.

Schröder FH, Norming U, Blumenstein BA, Busch C, Van Glabbeke M, Höisaeter PÅ, Johansson JE,  et al. Phase II studies on prostate cancer. Urology 1997;49(4A Suppl):3-14.

A Wolk, CS Mantzoros, S-O Andersson, LB Signorello, P Lagiou, R Bergström, D Trichopoulos, H-O Adami. Insulin-like Growth Factor 1 in Relation to Prostate Cancer -  A population-Based Case Control Study Study in Sweden. JNCI 90; 911-14, 1998

J Chan, E Giovannucci, S-O Andersson, J Yuen, H-O Adami, A Wolk. Dairy products, calcium, vitamin  D, and risk of prostate cancer (Sweden). Cancer Causes and Control  9;559-566. 1998

Hägglöf B, Andrén O, Bergström E, Marklund L, Wendelius M. Self-esteem in children with nocturnal enuresis and urinary incontinence: improvement of self-esteem after treatment. Eur Urol 1998;33 Suppl 3:16-9.

Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, et al. Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. Urology 1998;52(1):72-81.

Sahlberg-Blom E, Ternestedt BM, Johansson JE. The last month of life: continuity, care site and place of death. Palliat Med 1998;12(4):287-96.

L Signorello, K Brismar, R Bergström, S-O Andersson, A Wolk, D Trichopoulos and H-O Adami. Insulin-Like Growth Factor-Binding Protein-1 and Prostate Cancer. J Natl Cancer Inst. Brief communication. 91;1965-67, 1999

Sandblom G, Mattsson E, Nilsson J, Damber JE, Johansson JE, Lundgren R, et al. Prostate cancer registration in four Swedish regions 1996-- differences in incidence, age structure and management. Scand J Urol Nephrol 1999;33(5):306-11.

Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999;9(5):635-9.

Wadelius M, Autrup JL, Stubbins MJ, Andersson SO, Johansson JE, Wadelius C, et al. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics 1999;9(3):333-40.

2000

A Wolk, S-O Andersson, C Mantzoros, D Trichopoulos, H-O Adami.
Can improvements of IGF-1 and IGFBP-3 improve the sensitivity  of prostate-cancer screening? The Lancet Vol 356, 1902-1903, 2000

Hedlund PO, Henriksson P, (Johansson JE) Scandinavian Prostatic Cancer Group. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology 2000;55(3):328-33.

Helgesen F, Andersson SO, Gustafsson O, Varenhorst E, Gobén B, Carnock S, Johansson JE, et al. Follow-up of prostate cancer patients by on-demand contacts with a specialist nurse: a randomized study. Scand J Urol Nephrol 2000;34(1):55-61.

Prostate Cancer Trialists' Collaborative Group (Johansson JE). Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355(9214):1491-8.

Sahlberg-Blom E, Ternestedt BM, Johansson JE. Patient participation in decision making at the end of life as seen by a close relative. Nurs Ethics 2000;7(4):296-313.

Sahlberg-Blom E, Ternestedt BM, Johansson JE. "Am I going to die now?" Prognostication of survival time by members of the care team. Omega: Journal of Death & Dying 2000;42(3):219-35.

Söderström TG, ., Wadelius M, Lundgren S, Andersson SO, Johansson JE, Johansson S, et al. Association of CYP1B1 V432L polymorphism with prostate cancer metastases. In: Söderström T. Molecular endocrinology of target enzymes in androgen metabolism : Implications for prostate cancer [dissertation]. Stockholm: Karol. Inst.; 2000.

2001

Johansson JE. Natürlicher Krankheitsverlauf beim unbehandelten frühen Prostatakarzinom--die Örebro-Studie. Praxis (Bern 1994) 2001;90(36):1507-14.

Johansson JE, Wersall P, Brandberg Y, Andersson SO, Nordstrom L. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study. Scand J Urol Nephrol 2001;35(4):288-94.

Sahlberg-Blom E, Ternestedt BM, Johansson JE. Is good 'quality of life' possible at the end of life? An explorative study of the experiences of a group of cancer patients in two different care cultures. J Clin Nurs 2001;10(4):550-62.

2002

F.Algaba,S.Horenblas,G.Pizzocaro-Luigi Piva,E.Solsona and T.Windahl. EAU Guidelines on penile cancer.  European Urology 42,199-203, (2002)

Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Johansson JE, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11):781-9.

Iversen P, Tammela TL, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Johansson JE, et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Urol 2002;42(3):204-11.

Sandblom G, Holmberg L, Damber JE, Hugosson J, Johansson JE, Lundgren R, et al. Prostate-specific antigen as surrogate for characterizing prostate cancer subgroups. Scand J Urol Nephrol 2002;36(2):106-12.

Sandblom G, Holmberg L, Damber JE, Hugosson J, Johansson JE, Lundgren R, et al. Prostate-specific antigen for prostate cancer staging in a population-based register. Scand J Urol Nephrol 2002;36(2):99-105.

Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347(11):790-6.

Söderstrom T, Wadelius M, Andersson SO, Johansson JE, Johansson S, Granath F, et al. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002;12(4):307-12.

2003

H-O Adami, H Kuper, S-O Andersson, R Bergström, and J Dillner. Prostate Cancer Risk and Serologic Evidence of Human Papilloma Virus Infection. A Population-Based Case-Control Study. Cancer Epidemiology , Biomarkers and Prevention.  Vol 12, 872-875, sept 2003

T.Windahl and S-O Andersson. Combined Laser treatment of penile carcinoma. Results after long-term followup. J.Urol vol.169, 2118-2121, (2003)

Bill-Axelson A, Holmberg L, Johansson JE, Norlen BJ. Radikal prostatektomi minskar risken for död i prostatacancer. Ännu kan effekt på total överlevnad inte fastslås, visar randomiserad studie. Lakartidningen 2003;100(19):1714-6.

Chokkalingam AP, Nyrén O, Johansson JE, Gridley G, McLaughlin JK, Adami HO, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer 2003;98(8):1727-34.

Stattin P, Johansson R, Damber JE, Hellström M, Hugosson J, Lundgren R, Johansson J-E, et al. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry. Scand J Urol Nephrol 2003;37(6):461-5.

2004

S-O Andersson, B Rashidkani, J-E Johansson, L Karlberg, A Wolk. Prevalence of Lower Urinary Tract Symptoms in Swedish Men Aged 45-79 years and their influence on quality of life: A Population Based Study. Br J Urol 94(3):327-31, 2004

E. Solsona, F. Algaba, S. Horenblas, G. Pizzocaro and T. Windahl. EAU Guidelines on Penile Cancer. European Urology 46, 1-8, 2004.

T.Windahl, E.Skeppner, S-O. Andersson, K.Fugl-Meyer. Sexual function and satisfaction in men after laser treatment for penile carcinoma. J. Urol vol 172, 648-651,2004

Andersson G, Johansson JE, Garpenholt Ö, Nilsson K. Urinary incontinence--prevalence, impact on daily living and desire for treatment: a population-based study. Scand J Urol Nephrol 2004;38(2):125-30.

Andersson SO, Rashidkhani B, Karlberg L, Wolk A, Johansson JE. Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men. BJU Int 2004;94(3):327-31.

Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004;172(5 Pt 1):1871-6.

Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Johansson JE, et al. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology 2004;63(5):928-33.

Jakobsson J, Karypidis H, Johansson JE, Roh HK, Rane A, Ekström L. A functional C-G polymorphism in the CYP7B1 promoter region and its different distribution in Orientals and Caucasians. Pharmacogenomics J 2004;4(4):245-50.

Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291(22):2713-9.

Johansson JE, Andren O, Andersson S-O, Magnusson A, Dickman PW, Holmberg L, et al. Natural history of early localized prostate cancer--reply. JAMA 2004;292(13):1549-b-50.

Nilsson K, Johansson JE, Liljegren G. Medel och tid måste anslås for att EBM ska nå ut i vården. Örebro läns landsting har särskilt projekt för en mer evidensbaserad vård. Lakartidningen 2004;101(4):300-2.

2005

Brehmer M, Swartz R. Training on bench models improves dexterity in ureteroscopy. Eur. Urol 2005 Sept;48(3):458-63

Gårdmark, Carringer, Beckman, Malmström. Randomized phase 2 marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent stage ta urothelial bladder cancer. Urol 66(3) 2005

A Bill-Axelson, L Holmberg, M Ruutu, M Häggman, S-O Andersson, S Bratell, A Spångberg, C Busch, S Nordling, H Garmo, J Palmgren, H-O Adami, BJ Norlén and J-E Johansson. Radical prostatectomy versus Watchful Waiting in Early Prostate Cancer. N Engl J Med 2005;352:1977-84

Andersson G, Johansson JE, Sahlberg-Blom E, Pettersson N, Nilsson K. Urinary incontinence--why refraining from treatment? A population based study. Scand J Urol Nephrol 2005;39(4):301-7.

Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Johansson JE, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352(19):1977-84.

Jønler M, Nielsen OS, Groenvold M, Hedlund PO, Damber L, (Johansson JE) Scandinavian Prostate Cancer Group Study 5, et al. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5. Scand J Urol Nephrol 2005;39(1):42-8.

Lindmark F, Zheng SL, Wiklund F, Bälter KA, Sun J, Chang B, Johansson JE, et al. Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer 2005;93(4):493-7.

Rubin MA, Bismar TA, Andrén O, Mucci L, Kim R, Shen R, Johansson JE, et al. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14(6):1424-32.

Stattin P, Johansson R, Lodnert R, Andrén O, Bill-Axelsson A, Bratt O, Johansson JE, et al. Geographical variation in incidence of prostate cancer in Sweden. Scand J Urol Nephrol 2005;39(5):372-9.

Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson JE, et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005;97(7):525-32.

Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber JE, Hellström M, Johansson J-E, et al. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Scand J Urol Nephrol 2005;39(2):117-23.

2006

T.Windahl. Is carbon dioxide laser treatment of lichen sclerosus effective in the long run? Scand.J.Urol and Nephrol. 40:208-211, 2006.

Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Johansson J-E, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006;38(6):652-8.

Andrén O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 2006;175(4):1337-40.

Gupta A, Fant F, Axelsson K, Sandblom D, Rykowski J, Johansson JE, et al. Postoperative analgesia after radical retropubic prostatectomy: a double-blind comparison between low thoracic epidural and patient-controlled intravenous analgesia. Anesthesiology 2006;105(4):784-93.

Hedelin M, Bälter KA, Chang ET, Bellocco R, Klint Å, Johansson JE, et al. Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer. Prostate 2006;66(14):1512-20.

Hedelin M, Klint Å, Chang ET, Bellocco R, Johansson JE, Andersson SO, et al. Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden). Cancer Causes Control 2006;17(2):169-80.

Holmberg L, Bill-Axelson A, Garmo H, Palmgren J, Norlén BJ, Adami HO, Johansson JE, et al. Prognostic markers under watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am 2006;20(4):845-55.

Iversen P, Johansson JE, Lodding P, Kylmälä T, Lundmo P, Klarskov P, et al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol 2006;40(6):441-52.

Orsini N, RashidKhani B, Andersson SO, Karlberg L, Johansson JE, Wolk A. Long-term physical activity and lower urinary tract symptoms in men. J Urol 2006;176(6 Pt 1):2546-50.

Sun J, Wiklund F, Hsu FC, Bälter K, Zheng SL, Johansson JE, et al. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15(3):480-5.

Varenhorst E, Garmo H, Holmberg L, Stattin P, Johansson JE. Prostatacancer i Sverige 1998-2003. Drastisk förändring av sjukdoms-panoramat. Läkartidningen 2006;103(5):285-8.

Wolk A, Larsson SC, Johansson JE, Ekman P. Long-term fatty fish consumption and renal cell carcinoma incidence in women. JAMA 2006;296(11):1371-6.

Zheng SL, Liu W, Wiklund F, Dimitrov L, Bälter K, Sun J, Johansson JE, et al. A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate 2006;66(14):1556-64.

2007

Karypidis AH, Olsson M, Andersson SO, Rane A, Ekström L. Deletion  polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J. 2007 Mar 27

B.Persson, Jan-Gunnar Sjödin, Lars Holmberg and T.Windahl. The National Penile Cancer Register in Sweden 2000-2003. Scand.J.Urol and Nephrol. 41:278-282, 2007.

E.Skeppner, T.Windahl, S-O Anderssson and K S Fugl-Meyer. Treatment-seeking, aspects of sexual activity and life satisfaction in men with laser-treated penile carcinoma. Eur Urol 54:631-639.

Hugosson J, Johansson JE, Petterson B, Tornblom M, Widmark A, Stattin P. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007;41(6):456-77.

Andrén O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, Johansson JE, Mucci LA. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007;97(6):730-4.

Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y,
Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26(31):4596-9.

Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andrén O, Johansson JE, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007;41(6):456-77.

Andrén O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, Johansson JE, et al. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007;97(6):730-4.

Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Johansson JE, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26(31):4596-9.

Fall K, Garmo H, Andrén O, Bill-Axelson A, Adolfsson J, Adami HO, Johansson JE, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007;99(7):526-32.

Kang D, Chokkalingam AP, Gridley G, Nyrén O, Johansson JE, Adami HO, et al. Benign prostatic hyperplasia and subsequent risk of bladder cancer. Br J Cancer 2007;96(9):1475-9.

2008

Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, et al. Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol  Biomarkers Prev. 2008 Jul;17(7):1682-8.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008   Jun 4;100(11):815-25.

P. Andersson,  A.Kolaric, T.Windahl, P.Kirrander, P.Söderkvist and M.Karlsson. PIK3CA, HRAS and KRAS gene mutations in human penile cancer. J.Urol 179:2030-2034, 2008.

J.A.P. Leijte, P. Kirrander, N. Antonini, T.Windahl and S.Horenblas. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 54:161-169, 2008.

Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andrén O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008;13(6):519-28.

Fall K, Strömberg F, Rosell J, Andrén O, Varenhorst E, South-East Region Prostate Cancer G. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol 2008;42(4):352-7.

Andersson G, Johansson JE, Nilsson K, Sahlberg-Blom E. Accepting and adjusting: older women's experiences of living with urinary incontinence. Urol Nurs 2008;28(2):115-21.

Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Johansson JE, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100(16):1144-54.

Franzén K, Johansson JE, Andersson G, Nilsson K. Urinary incontinence: Evaluation of an information campaign directed towards the general public. Scand J Urol Nephrol 2008;42(6):534-8.

Larsson SC, Andersson SO, Johansson JE, Wolk A. Cultured milk, yogurt, and dairy intake in relation to bladder cancer risk in a prospective study of Swedish women and men. Am J Clin Nutr 2008;88(4):1083-7.

Larsson SC, Andersson SO, Johansson JE, Wolk A. Fruit and vegetable consumption and risk of bladder cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2008;17(9):2519-202.

Larsson SC, Andersson SO, Johansson JE, Wolk A. Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. Eur J Cancer 2008;44(17):2655-60.

Laven BA, Orsini N, Andersson SO, Johansson JE, Gerber GS, Wolk A. Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. J Urol 2008;179(5):1891-5; discussion 5-6.

Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Johansson JE, et al. Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev 2008;17(7):1682-8.

Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Johansson JE, et al. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Cancer Epidemiol Biomarkers Prev 2008;17(1):249-51.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Johansson JE, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008;100(11):815-25.

Stattin P, Holmberg E, Bratt O, Adolfsson J, Johansson JE, Hugosson J. Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol 2008;180(6):2423-9; discussion 9-30.

Sun J, Zheng SL, Wiklund F, Isaacs SD, Purcell LD, Gao Z, Johansson JE, et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008;40(10):1153-5.

Wiklund F, Lageros YT, Chang E, Bälter K, Johansson JE, Adami HO, et al. Lifetime total physical activity and prostate cancer risk: a population-based case-control study in Sweden. Eur J Epidemiol 2008;23(11):739-46.

2009

Hygiene and urinary tract infections after cystectomy in 452 Swedish survivors of bladder cancer. Thulin H, Steineck G, Kreicbergs U, Onelöv E, Ahlstrand C, Carringer M, Holmäng S, Ljungberg B, Malmström PU, Robinsson D, Wijkström H, Wiklund NP, Henningsohn L. Division of Clinical Cancer Epidemiology, Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.bju int 2009 oct 23

Fall K, Fang F, Lorelei M, Weimin Y, Andrén O, Johansson JE, Andersson SO, Klein G, Stampfer M, Adami HO, Valdimardsdóttir U. Immediate risk for carciovascular events and suicide following a prostate cancer diagnosos: prospective cohort study PLoS Med. 2009 Dec;6(12):e1000197.

Andersson G, Johansson JE, Nilsson K, Sahlberg-Blom E. Perceptions of urinary incontinence among Syrian christian women living in Sweden: An interview study. J Transcult Nurs 2009;20(3):296-303.

Andrén O, Garmo H, Mucci L, Andersson SO, Johansson JE, Fall K. Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer 2009;100(1):170-3.

Carlsson S, Adolfsson J, Bratt O, Johansson JE, Ahlstrand C, Holmberg E, et al. Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden. Scand J Urol Nephrol 2009:1-7.

Franzén K, Johansson JE, Andersson G, Pettersson N, Nilsson K. Urinary incontinence in women is not exclusively a medical problem: A population-based study on urinary incontinence and general living conditions. Scand J Urol Nephrol 2009;43(3):226-32.

Johansson E, Bill-Axelson A, Holmberg L, Onelov E, Johansson JE, Steineck G. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: The Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) Clinical Trial. Eur Urol 2009;55(2):422-32.

Landberg R, Kamal-Eldin A, Andersson SO, Johansson JE, Zhang JX, Hallmans G, et al. Reproducibility of plasma alkylresorcinols during a 6-week rye intervention study in men with prostate cancer. J Nutr 2009;139(5):975-80.

Larsson SC, Johansson JE, Andersson SO, Wolk A. Meat intake and bladder cancer risk in a Swedish prospective cohort. Cancer Causes Control 2009;20(1):35-40.

Tilling K, Garmo H, Metcalfe C, Holmberg L, Hamdy FC, Neal DE, Johansson JE, et al. Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: A comparison of observational cohorts. Eur Urol 2009.

Zheng SL, Sun J, Wiklund F, Gao Z, Stattin P, Purcell LD, Johansson JE, et al. Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Cancer Res 2009;15(3):1105-11.

Fall K, Fang F, Lorelei M, Weimin Y, Andrén O, Johansson JE, et al. Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective chohort study. PloS Med. 2009 Dec;6(12):e1000197. Epub 2009 Dec 15.

Orsini N, Bellocco R, Bottai M, Pagano M, Andersson SO, Johansson JE, Giovannucci E, Wolk A. A prospective study of lifetime physical activity and prostate cancer incidence and mortality. Br J Cancer 2009;101(11):1932-8.

Holmberg L, Adolfsson J, Mucci L, Garmo H, Adami HO, Moller H, Johansson JE, Stampfer M. Season of diagnosis and prognosis in breast and prostate cancer. Cancer Causes Control 2009;20(5):663-70.
 
Hagel E, Garmo H, Bill-Axelson A, Bratt O, Johansson JE, Adolfsson J, Lambe M, Stattin P. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol 43(5): 342-9, 2009.

Xu J, Sun J, Kader AK, Lindstrom S, Wiklund F, Hsu FC, Johansson JE, Zheng SL, Thomas G, Hayes RB, Kraft P, Hunter DJ, Chanock SJ, Isaacs WB, Gronberg H. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 2009;69(14):1565-72.

Zheng SL, Stevens VL, Wiklund F, Isaacs SD, Sun J, Smith S, Pruett K, Wiley KE, Kim ST, Zhu Y, Zhang Z, Hsu FC, Turner AR, Johansson JE, Liu W, Kim JW, Chang BL, Duggan D, Carpten J, Rodriguez C, Isaacs W,Gronberg H, Xu J. Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev 2009;18(6):1815-20.

Kasperzyk JL, Fall K, Mucci LA, Hakansson N, Wolk A, Johansson JE, Andersson SO, Andren O. One-carbon metabolism-related nutrients and prostate cancer survival. Am J Clin Nutr 2009;90(3):561-9.

2010

Nyman ME, Johansson, JE, Gustavsson M. A randomised controllered trial on the effect of clamping the indwelling urinary catheter in patients with hip fracture. Clin Nurs. 2010 Feb;19(3-4):405-13. 

Sboner A, Demichelis F, Calza S, Pawiat Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci L, Kantoff PW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR, Rubin MA, Andren O. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010 Mar 16;3(1):8

Tilling K, Garmo H, Metcalfe C, Holmberg L, Hamdy FC, Neal DE, Adolfsson J, Martin RM, Davis M, Fall K, Lane JA, Adami HO, Bill-Axelson A, Johansson JE, Denovan JL. Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational Eur Urol 2010 Mar;57(3):446-52

Hälleberg Nyman M, Johansson JE, Gustafsson M. A randomised 
controlled trial on the effect of clamping the indwelling urinary catheter in patients with hip fracture. Journal of Clinical Nursing 2010;19:405-413.

Meyer MS, Mucci LA, Andersson SO, Andrén O, Johansson JE, Tretli S, Adami HO. Homogeneous Prostate Cancer Mortality in the Nordic Countries Over Four Decades. Eur Urol. 2010 Jun 4.

Franzén K, Johansson JE, Lauridsen I, Canelid J, Hewiwall B, Nilsson K. Electrical stimulation compared with tolterodine for treatment of urge/urge incontinence amongst women, a randomized controlled trial. Int Urogynecol J Plevic Floor Dysfunct. 2010 Jun 29.

Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J; National Prostate Cancer register (NPCR) of Sweden. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden Follow-up study. J Natl Cancer Inst 2010 Jul 7;102(13):950-8.

Bratt O, Berglund A, Adolfsson J, Johansson JE, Törnblom M, Stattin P for the steering committee of the Swedish National Prostate Cancer Register. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: A population-based study from the National Prostate Cancer Register of Sweden. Scand J of Urology and Nephrology, July 13 2010.

Flaberg E, Markasz L, Petranyi G, Stuber G, Dicső F, Alchihabi N, Oláh E, Csízy I, Józsa T, Andrén O, Johansson JE, Andersson SO, Klein G, Szekely L. High throughput live cell imaging reveals differential inhibition of tumor cell proliferation by human fibroblasts. Int J Cancer. 2010 Aug 16

Jerlström T, Andersson G, Carringer M. Functional outcome of orthotopic bladdersubstitution: a comparison between the S-shaped and U-shaped neobladder. Scand J Urol Nephrol. 2010 Sep;44(4):197-203.

Carlsson J, Helenius G, Karlsson M, Lubovac Z,  Andrén O, Olsson B, Klinga-Levan K. Validation of suitable endogenous control genes for expression studies of miRNA in prostate cancer tissues. Cancer Genet Cytogenet 2010 Oc 15;202(2):71-5

Holmström B, Holmberg E, Egevad L, Adolfsson J, Johansson JE, Hugosson J, P Stattin on behalf of the National Prostate Cancer Register of Sweden. Outcome of Primary Versus Deferred Radical Prostatectomy in the National Prostate Cancer Register of Sweden Followup study. Journal of Urology vol 184, 1322-1327 Okt 2010.

Svensson MA, Lafargue CJ, Macdonald T, Pflueger D, Kitabyashi N, Santa-Cruz MA, Garsha KE, Sathyanarayana UG, Riley JP, Yun CS, Nagy D, Kosmeder JW, Pestano GA, Tewari AK, Demichelis F, Rubin MA. Testing mutual exclusivity of ETS rearranged prostate cancer. Laboratory Investigation 2010 Oct 25.

Kirrander P, Kolaric A, Helenius G, Windahl T, Andrén O, Lillsunde-Larsson G, Elgh F, Karlsson M. Human pappilomavirus prevalence, distribution and correlation to histopathological parameters in a large Swedish cohort of men with penile carcinoma. BJU Int. 2010 Nov 2.

Thulin H, Kreicbergs U, Onelöv E, Ahlstrand C, Carringer M, Holmäng S, Ljungberg B, Malmström PU, Robinsson D, Wijkström H, Wiklund NP, Steineck G, Henningsohn L. Defecation disurbances after cystectomy for urinary bladder cancer. BJU Int 2010 Nov 2.

Stranne J, Johansson E, Nilsson A, Bill-Axelson A, Carlsson S, Holmberg L, Johansson JE, Nyberg T, Ruutu M, Wiklund NP, Steineck G. Inguinal hernia after radical prostatectomy for prostate cancer: results from a randomized setting and a nonrandomized setting. Eur Urol. 2010 Nov;58(5):719-26

Stranne J, Johansson E, Nilsson A, Bill-Axelson A, Carlsson S, Holmberg L, Johansson JE, Nyberg T, Ruutu M, Wiklund P, Steineck G. Inguinal hernia after radical prostatectomy for prostate cancer: results from a randomized setting and a nonrandomized setting. Eur Urol 3557 1-8, 2010

Landberg R, Andersson SO, Zhang JX, Johansson JE, Stenman UH, Adlercreutz H, Kamal-Eldin A, Aman P, Hallmans G. Department of Food Science, Swedish University of Agriculture Science, Uppsala, Sweden. Rye whole grain and intake dompared with refined wheat decreases urinary C-peptide, plasma insulin, and prostate specific antigen in men with prostate cancer. N Nutr. 2010 Dec; 140(12):2180-6.

Mucci LA, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ, Ma J. Plasma levels of acid-labile subunit, free insulin-like growth factor-1, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 2010;19(2):484-91.

Fiorentino M, Judson G, Penney K, Flavin R, Stark JR, Fiore C, Fall K, Martin NE, Ma J, Sinnott JA, Giovannucci E, Stampfer MJ, Sesso H, Kantoff PW, Finn S, Loda M, Mucci LA. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res 2010;70(8):3136-9.

2011  

Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin PC, Svensson MA, et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res 2011 Jan;21(1):56-67.

Epstein MM, Kasperzyk JL, Andrén O, Giovannucci EL, Wolk A, Håkansson N, Andersson SO, Johansson JE, Fall K, Mucci LA. Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, MA. Dietary zinc and prostate cancer survival in a Swedish cohort.
Am J Clin Nutr. 2011 Mar:93(3):586-93.

Andersson SO, Andrén O, Lyth J, Stark JR, Henriksson M, Adami HO, Carlsson P, Johansson JE. Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG-4). Scand J Urol Nephrol. 2011 Apr;45(3):177-83.

Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Setlur S, Sesso HD, Andersson SO, Martin N, Kantoff PW, Johansson JE, Adami HO, Rubin MA, Loda M, Golub TR, Andren O, Stampfer MJ, Mucci LA. mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. J Clin Oncol 2011 May 2.

Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami HO, Johansson JE. Radical prostatectomy versus watchful waiting in early prostate Cancer. N Engl J Med 2011 May 5;364(18):1770-2.

Carlsson J, Davidsson S, Helenius G, Karlsson M, Lubovac Z, Andren O, Olsson B, Klinga-Levan K. A miRNA expression signature that separates between normal and malignant prostate tissues. Cancer Cell Int 2011 May 27;11(1):14.

Thulin H, Kreicbergs U, Onelöv E, Ahlstrand C, Carringer M, Holmäng S, Ljungberg B, Malmström PU, Robinsson D, Wijkström H, Wiklund NP, Steineck G, Henningsohn L. Defecation disturbances after cystectomy for urinary bladder cancer. BJU Int. 2011 Jul; 108(2):196-203

Desai M, De Lisa A, Turma B, Rioja J, Walfridsson H, et al. The clinical research office of the endourological society percutaneous nephrolithotomy global study:staghorn versus nonstaghorn stones. J Endourol 2011 Aug:25(8):1263-8

Lyth J, Andersson SO, Andren O, Johansson JE, Carlsson P, Shahsavar N. A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer. Scand J Urol Nephrol. 2011 September 12

Johansson E, Steineck G, Holmberg L, Johansson JE, Nyberg T, Ruutu M, Bill Axelson A, SPCG-4 Investigators. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 2011 Sept;12(9):891-9

Hälleberg Nyman M, Johansson JE, Persson K, Gustafsson M. A prospective study of nosocomial urinary tract infection in hip fracture patients. J Clin Nurs. 2011 Sep;20(17-18):2531-9

Fant F, Axelsson K, Sandblom D, Magnuson A, Andersson SO, Gupta A. Thoracic epidural analgesia or patient-controlled local analgesia for radical retropubic prostatectomy: a randomized, double-blind study. Br J Anaesth. 2011 September 23

Discacciati A, Orsini N, Andersson SO, Andren O, Johansson JE, Wolk A. Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer 2011 September 27;105(7):1061-8

Davidsson S, Fiorentino M, Andren O, Fang F, Mucci LA, Varenhorst E, Fall K, Rider JR. Inflammation, Focal Atrophic Lesions, and Prostatic Intraepithelial Neoplasia with Respect to Risk of Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. October 2011 20:2280-2287

Moazzami, A. A., J. X. Zhang, Kamal-Eldin A, Aman P, Hallmans G, Johansson JE, Andersson SO. "Nuclear Magnetic Resonance-Based  Metabolomics Enables Detection of the Effects of a Whole Grain Rye and Rye Bran  Diet on the Metabolic Profile of Plasma in Prostate Cancer Patients." Journal of  Nutrition. 2011 October 19.